Abstract 425P
Background
In Indonesia, traditional medicine is still trusted, especially as a cancer therapy. Cancer treatment, which has many side effects, triggers the patient's anxiety. The patient's decision may contradict the advice of a health professional, affecting the prognosis of cancer. Health professionals are responsible for delivering explicit and adequate information to prevent misinformation that may affect decision-making for patient care. The Universitas Sebelas Maret Trust and Readiness Assessment for Cancer Patients (UNS – TRAfCP35) is an instrument designed to assess a patient's understanding of cancer, confidence in alternative medicine, and a patient's confidence in medical therapies. This study aims to see the validity and reliability of UNS – TRAfCP35 in assessing patients' understanding of cancer, trust in alternative medicine, and trust in medical treatment for cancer patients in Indonesia.
Methods
This is a cross-sectional hospital-based study conducted on 100 patients at Dr. Moewardi Hospital, using UNS-TRAfCP35. The questionnaire consisted of 35 questions divided into 3 parts: 15 questions regarding patients' understanding of cancer, 8 questions regarding their belief in alternative medicine, and 12 questions about patients' trust in medical treatment. Validity and reliability were used using Pearson and Cronbach alpha.
Results
Validity tests showed that the understanding of cancer (r = 0.236–0.456), the patient's confidence in alternative medicine (r = 0.301–0.688) and the patient's confidence in medical care (r = 0.324–0.765) had r > 0.196. Reliability tests showed that the questions from each section had Cronbach alpha values of 0.712, 0.830, and 0.844, respectively. Alfa Cronbach > 0.60. The values indicate that all questions in the questionnaire are valid, reliable, consistent, and qualified for further analysis for the treatment of cancer patients.
Conclusions
This study shows that UNS – TRAfCP35 is valid and reliable for assessing patients' understanding of cancer, trust in alternative medicine, and medical care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Limited duration of treatment with checkpoint inhibitors in complete responders, yet prolonged survival: A real-world study from India
Presenter: Nitin Murthy
Session: Poster viewing 06
463P - Cost effectiveness of palbociclib and ribociclib in metastatic breast cancer in India using ICER and QALY
Presenter: Krishnamani Kalpathi
Session: Poster viewing 06
464TiP - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Presenter: Alexander van Akkooi
Session: Poster viewing 06
465TiP - Evaluation of quality of life and functional outcomes following limb salvage surgery in extremities sarcomas
Presenter: naveen kushwaha
Session: Poster viewing 06
YO2 - A case of locally advanced breast cancer with biomarker conversion successfully treated with neoadjuvant chemotherapy-immunotherapy combination
Presenter: Long Nguyen
Session: Poster viewing 06
YO3 - Metastatic Breast cancer to esophagus: A case report and review of literature
Presenter: Bhuvana J
Session: Poster viewing 06
YO4 - Succinate Dehydrogenase deficient GISTs is a diagnostic and therapeutic dilemma? : A case report.
Presenter: Nurazzahra Kamarudin
Session: Poster viewing 06
YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Presenter: Tisha Gay Tancongco
Session: Poster viewing 06
YO7 - Orbital Metastasis in Prostrate Cancer: A Case Report
Presenter: Shabnam Rehman
Session: Poster viewing 06
YO10 - BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor
Presenter: Debapriya Mondal
Session: Poster viewing 06